Richard A. Van Etten
Director, Chao Family Comprehensive Cancer Center
Professor, Division of Hematology/Oncology, Medicine
School of Medicine
School of Medicine
Professor, Biological Chemistry
School of Medicine
School of Medicine
M.D., Stanford University School of Medicine, 1984, Medicine
Ph.D., Stanford University, 1984, Biophysics
B.S., Massachusetts Institute of Technology (M.I.T.), 1978, Mathematics & Biology
Ph.D., Stanford University, 1984, Biophysics
B.S., Massachusetts Institute of Technology (M.I.T.), 1978, Mathematics & Biology
Phone: (949) 824-2655 (Academic Office); (714) 456-8031 (Med Ctr); (714) 456-8000 (Appointments)
Fax: (714) 456-5280
Email: vanetten@uci.edu
Fax: (714) 456-5280
Email: vanetten@uci.edu
University of California, Irvine
839 Health Sciences Road
Sprague Hall, Room 106
Irvine, CA 92697
839 Health Sciences Road
Sprague Hall, Room 106
Irvine, CA 92697
Publications
Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. New Engl. J. Med. 2005; 353:172-187.
Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 2007; 7:332-344.
Chan WW, Wise SC, Kaufman MD, Ahn Y-M, Ensinger CL, Haack T, Hood MM, Jones J, Lord JW, Lu WP, Miller D, Patt WC, Smith BD, Petillo PA, Rutkoski TJ, Telikepalli H, Vogeti L, Yao T, Chun L, Clark R, Evangelista P, Gavrilescu LC, Lazarides K, Zaleskas VM, Stewart L, Van Etten RA, Flynn DL. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 2011; 19:556-568. PMC3077923
Okimoto RA, Van Etten RA. Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Curr. Opin. Hematol. 2011; 18:89-97. PMC3496274
Lu Y-F, Betancur M, Lazarides K, Klingemann H, Van Etten RA. Distinct graft-vs-leukemic stem cell effect of early or delayed donor leukocyte infusion in a mouse chronic myeloid leukemia model. Blood 2012; 119:273-284. PMC3251232
Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, Hennighausen L, Zaleskas VM, Van Etten RA. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F. Blood 2012; 119(15):3550-3560. PMC3325042
Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H, Ailawadhi S, Akard L, Baer M, Baccarani M, Emmons R, Etienne G, Guerci A, Guilhot F, Hellmann A, Huguet-Rigal F, Khoury H, Laneuville P, Coutre PL, Legros L, Leitner A, Maloisel F, Marin D, Masszi T, Parikh P, Rivera C, Rousselot P, Facon T, Van Etten R, Warzocha K,Wetzler M, Wiernik P. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012;120(13):2573-2580.
Ahmed W, Van Etten RA. Alternative approaches to eradicating the malignant clone in CML: TKI combinations and beyond. Hematology Am Soc Hematol Educ Program 2013;2013:189-200.
Mughal TI, Girnius S, Rosen S, Kumar S, Weistner A, Abdel-Wahab O, Kiladjian J-J, Wilson WH, Van Etten RA. Emerging therapeutic paradigms to target the deregulated JAK/STATpathways in hematologic malignancies. Leuk. Lymphoma 2013; Epub Nov 11. doi:10.3109/10428194.2013.863307.
Ahmed W, Van Etten RA. Signal transduction in the chronic leukemias: Implications for targeted therapies. Curr. Hematol. Malig. Rep. 2013;8(1):71-80. NIHMSID 434916
Kantarjian H, et al. The price of drugs for chronic myeloid leukemia (CML); A reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood 2013; 121:4439-4442.
Klingemann H, Grodman C, Cutler E, Duque M, Kadidlo D, Klein A, Sprague K, Miller K, Comenzo R, Kewalramani T, Yu N, Van Etten RA, McKenna D. Autologous stem celltransplant recipients tolerate haploidentical related-donor natural killer cell enriched infusions. Transfusion 2013;53(2):412-418. NIHMS378771
Mughal TI, Girnius S, Rosen S, Kumar S, Weistner A, Abdel-Wahab O, Kiladjian J-J, Wilson WH, Van Etten RA. Emerging therapeutic paradigms to target the deregulated JAK/STAT pathways in hematologic malignancies. Leuk. Lymphoma 2013; Epub Nov 11. doi:10.3109/10428194.2013.863307.
Ahmed W, Van Etten RA. Signal transduction in the chronic leukemias: Implications for targeted therapies. Curr. Hematol. Malig. Rep. 2013;8(1):71-80. NIHMSID 434916
Krause DS, Fulzele K, Catic A, Sun CC, Dombkowski D,Hurley MP, Lezeau S, Attar EC, Wu JW, Lin HY, Divieti-Pajevic P, Hasserjian RP, Schipani E, Van Etten RA, Scadden DT. Differential regulation of myeloid leukemia by the bone marrow microenvironment. Nature Medicine 2013;19:1513-1517.
Krause DS, Lazarides K, Lewis JB, von Andrian UH, Van Etten RA. Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemia-initiating cells. Blood 2014;123(9):1361-1371.
Hsieh M-Y, Van Etten RA. IKK-dependent activation of NF-?B contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1. Blood 2014; 123(15):2401-2411.
Joshi I, Yoshida T, Jena N, Qi X, Zhang J, Van Etten RA, Georgopoulos K. Loss of Ikaros DNA-binding function confers integrin-dependent survival of pre-B cells and progression to acute lymphoblastic leukemia. Nature Immunology 2014;15(3):294-304.
Jena N, Sheng J, Hu JK, Zhou W, Lee G, Tsichlis N, Pathak A, Brown N, Deshpande A, Luo C, Hu G-F, Hinds PW, Van Etten RA, Hu MG. CDK6-mediated repression of CD25 is required for pathogenesis of Notch1-induced T cell acute lymphoblastic leukemia. Leukemia 2016;30(5):1033-1043.
Gu S, Chan WW, Mohi G, Rosenbaum J, Sayad A, Lu Z, Virtanen C, Li S, Neel BG, Van Etten RA. Distinct signaling pathways mediated by the adapter GAB2 are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Blood 2016; 127(14):1803-1813.
Hu Y, Zhang Z, Kashiwagi M, Yoshida T, Joshi I, Jena N, Somasundaram R, Okinola EA, Sigvardsson M, Fitamant J, El-Bardeesy N, Gounari F, Van Etten RA, Georgopoulos K. Super-enhancer reprogramming drives a B cell-epithelial transition and high-risk leukemia. Genes Dev. 2016;30(17):1971-1990.
Cortes J, Talpaz M, Smith HP, Synder DS, Khoury J, Bhalla K, Pinilla J, Larson RA, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian H, Rosen O, Van Etten RA. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica 2017;102(3):519-528.
Gu S, Sayad A, Chan G, Yang W, Zhibin Lu Z, Virtanen C, Van Etten RA, Neel BG. SHP2 is required for BCR-ABL1-induced hematopoietic neoplasia. Leukemia 2018;32(1):203-213.
Professional Societies
American Associate for Advancement of Science (AAAS)
American Society of Hematology (ASH)
American Society of Clinical Oncology (ASCO)
Member, Eastern Cooperative Oncology Group, Leukemia Comm.
Contributing Editor, UpToDate
Editorial Board, Journal of Clinical Oncology
Medical Oncology Association of Southern California (MOASC)
Other Experience
Intern, Internal Medicine
Brigham & Women's Hospital, Boston 1984—1986
Brigham & Women's Hospital, Boston 1984—1986
Fellow, Hematology
Brigham & Women's Hospital, Boston 1987—1988
Brigham & Women's Hospital, Boston 1987—1988
Visiting Scientist
Whitehead Institute for Biomedical Research Cambridge, MA 1988—1991
Whitehead Institute for Biomedical Research Cambridge, MA 1988—1991
Graduate Programs
Cancer Biology
Research Centers
Chao Family Comprehensive Cancer Center
Link to this profile
https://faculty.uci.edu/profile/?facultyId=6033
https://faculty.uci.edu/profile/?facultyId=6033
Last updated
07/12/2022
07/12/2022